IL13 and Alzheimer disease: Nemolizumab is a modern monoclonal antibody specifically synthesised for the management of pruritus, inhibiting IL31, a cytokine widely involved in the pathogenesis of this symptom in acute and chronic AD, and even playing a superior role to IL4 and IL13 [20,21].